Zydus Lifesciences informs about press release

28 May 2025 Evaluate
Zydus Lifesciences has informed that it enclosed a copy of press release dated May 28, 2025, titled ‘Zydus receives USFDA ‘Fast Track Designation’ for Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic Lateral Sclerosis (ALS)’. The contents of the press release give full details. 

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

904.00 -7.50 (-0.82%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×